Sierra Oncology (SRRA) Sets New 1-Year Low at $1.46

Shares of Sierra Oncology Inc (NASDAQ:SRRA) reached a new 52-week low during trading on Monday . The stock traded as low as $1.46 and last traded at $1.51, with a volume of 19090 shares trading hands. The stock had previously closed at $1.52.

Several analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Sierra Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. ValuEngine raised shares of Sierra Oncology from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.68 and a current ratio of 14.68. The company has a market cap of $113.04 million, a PE ratio of -1.81 and a beta of 1.73.

Sierra Oncology (NASDAQ:SRRA) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, research analysts expect that Sierra Oncology Inc will post -0.77 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of SRRA. Morgan Stanley grew its holdings in shares of Sierra Oncology by 11.3% during the 3rd quarter. Morgan Stanley now owns 992,516 shares of the biotechnology company’s stock worth $1,687,000 after purchasing an additional 100,709 shares during the period. Prosight Management LP grew its holdings in shares of Sierra Oncology by 50.6% during the 3rd quarter. Prosight Management LP now owns 2,720,089 shares of the biotechnology company’s stock worth $4,624,000 after purchasing an additional 913,527 shares during the period. Algert Global LLC grew its holdings in shares of Sierra Oncology by 173.8% during the 3rd quarter. Algert Global LLC now owns 394,258 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 250,267 shares during the period. Renaissance Technologies LLC boosted its holdings in Sierra Oncology by 27.5% in the 3rd quarter. Renaissance Technologies LLC now owns 2,252,244 shares of the biotechnology company’s stock worth $3,829,000 after acquiring an additional 485,344 shares during the period. Finally, Citadel Advisors LLC boosted its holdings in Sierra Oncology by 42.7% in the 3rd quarter. Citadel Advisors LLC now owns 1,832,042 shares of the biotechnology company’s stock worth $3,114,000 after acquiring an additional 548,591 shares during the period. Hedge funds and other institutional investors own 60.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sierra Oncology (SRRA) Sets New 1-Year Low at $1.46” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2018/12/11/sierra-oncology-srra-sets-new-1-year-low-at-1-46.html.

About Sierra Oncology (NASDAQ:SRRA)

Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.

Recommended Story: What is intrinsic value?

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply